Search results for " HEART FAILURE"

showing 10 items of 154 documents

Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications

2015

Abstract Systolic and diastolic myocardial dysfunction has been demonstrated to be associated with an activation of the circulating and local renin–angiotensin–aldosterone system (RAAS), and with a subsequent inappropriately increased production of reactive oxygen species (ROS). While, at low concentrations, ROS modulate important physiological functions through changes in cellular signalling and gene expression, overproduction of ROS may adversely alter cardiac mechanics, leading to further worsening of systolic and diastolic function. In addition, vascular endothelial dysfunction due to uncoupling of the nitric oxide synthase, activation of vascular and phagocytic membrane oxidases or mit…

Mitochondrial ROSmedicine.medical_specialtyXanthine OxidasePhosphodiesterase InhibitorsDiastoleAngiotensin-Converting Enzyme InhibitorsReviewmedicine.disease_causeNitric OxideCardiovascular SystemAntioxidantsInternal medicinemedicineHumansEndothelial dysfunctionHeart Failure DiastolicEjection fractionNitratesbusiness.industryDiastolic heart failureNADPH OxidasesStroke VolumeVitaminsHydralazinemedicine.diseaseHydralazineExercise TherapyMitochondriaOxidative StressHeart failureCardiologyDrug Therapy CombinationNitric Oxide SynthaseCardiology and Cardiovascular MedicinebusinessReactive Oxygen SpeciesOxidative stressmedicine.drugHeart Failure Systolic
researchProduct

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Biomarker-guided management in acute heart failure: is there light at the end of the tunnel?

2020

OncologyHeart Failuremedicine.medical_specialtybusiness.industryMEDLINECardiologyBiomarkers; Europe; Humans; Procalcitonin; Cardiology; Heart Failuremedicine.diseaseProcalcitoninEuropeInternal medicineHeart failuremedicineBiomarker (medicine)HumansCardiology and Cardiovascular MedicinebusinessProcalcitoninBiomarkers
researchProduct

Wet BNP, fluid and hemodynamic status at discharge in Acute Heart Failure

2010

We comment the noteworthy results of Pimenta et al. concerning the significance of discharge BNP levels in acute HF patients. The innovation of Pimento's study is the systematic research of the potential relationship between BNP and clinical and hemodynamic parameters. We focused the attention on the importance of wet "BNP" in managing HF and its ability to reflect congestion and multiple underlying patho-physiological disturbances. The first observation, regarding the statistical order, underlines the importance of renal insufficiency at discharge in genesis of higher BNP levels. Secondly, we note that the relationship between natriuretic peptides and the non-invasive measurement of the fl…

Oncotic pressuremedicine.medical_specialtySettore MED/09 - Medicina InternaHeart diseasebusiness.industryHemodynamicsPlasma levelsmedicine.diseaseBrain natriuretic peptideSurgeryHeart failureInternal medicineAcute Heart failure Brain natriuretic peptideAmbulatoryCardiologyMedicineCardiology and Cardiovascular MedicinebusinessKidney diseaseInternational Journal of Cardiology
researchProduct

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

2015

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular deat…

Oralmedicine.medical_specialtyHeart diseasesGlycosylatedAdministration Oralheart failureType 2 diabetesDipeptidyl peptidase-4 inhibitorKaplan-Meier EstimatePlaceboSitagliptin PhosphateSitagliptin Cardiovascular Outcomeschemistry.chemical_compoundDrug TherapyDouble-Blind MethodInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentsGlycated HemoglobinHemoglobin A GlycosylatedAdministration Oral; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Drug Therapy Combination; Follow-Up Studies; Heart Diseases; Heart Failure; Hemoglobin A Glycosylated; Hospitalization; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Pyrazines; Sitagliptin Phosphate; Triazoles; Medicine (all)business.industryMedicine (all)SemaglutideSitagliptin PhosphateHemoglobin AGeneral MedicineTriazolesta3121medicine.diseaseSurgeryHospitalizationCardiovascular diseaseschemistryDiabetes Mellitus Type 2SitagliptinPyrazinesAdministrationCombinationDrug Therapy CombinationGlycated hemoglobinbusinessType 2Alogliptinmedicine.drugFollow-Up StudiesNew England Journal of Medicine
researchProduct

Isolation and Characterization of CD276+/HLA-E+ Human Subendocardial Mesenchymal Stem Cells from Chronic Heart Failure Patients: Analysis of Differen…

2012

Mesenchymal stem cells (MSCs) are virtually present in all postnatal organs as well as in perinatal tissues. MSCs can be differentiated toward several mature cytotypes and interestingly hold potentially relevant immunomodulatory features. Myocardial infarction results in severe tissue damage, cardiomyocyte loss, and eventually heart failure. Cellular cardiomyoplasty represents a promising approach for myocardial repair. Clinical trials using MSCs are underway for a number of heart diseases, even if their outcomes are hampered by low long-term improvements and the possible presence of complications related to cellular therapy administration. Therefore, elucidating the presence and role of MS…

Pathologymedicine.medical_specialtyB7 AntigensHeart VentriclesGene ExpressionCell SeparationBiologyCell therapyHLA-EAntigens CDOsteogenesisCellular cardiomyoplastymedicineHumansImmunologic FactorsMyocardial infarctionCells CulturedHeart FailureAdipogenesisMesenchymal stem cells human heart stromal progenitors post-infarct chronic heart failure cardiomyocyte markers immune modulation inflammation cardiac remodelling regenerative medicineSettore BIO/16 - Anatomia UmanaHistocompatibility Antigens Class IMesenchymal stem cellMesenchymal Stem CellsCell BiologyHematologyAnatomymedicine.diseaseClinical trialmedicine.anatomical_structureVentricleHeart failureChondrogenesisBiomarkersDevelopmental BiologyStem Cells and Development
researchProduct

Comprehensive three‐dimensional morphology of neoangiogenesis in pulmonary veno‐occlusive disease and pulmonary capillary hemangiomatosis

2019

Abstract Pulmonary veno‐occlusive disease (PVOD) is a rare lung disease characterized by fibrotic narrowing of pulmonary veins leading to pulmonary hypertension (PH) and finally to death by right heart failure. PVOD is often accompanied by pulmonary capillary hemangiomatosis (PCH), a marked abnormal proliferation of pulmonary capillaries. Both morphological patterns often occur together and are thought to be distinct manifestations of the same disease process and accordingly are classified together in group 1′ of the Nice classification of PH. The underlying mechanisms of these aberrant remodeling processes remain poorly understood. In this study, we investigated the three‐dimensional struc…

Pathologymedicine.medical_specialtyLung NeoplasmsHypertension Pulmonarypulmonary veno‐occlusive diseasePulmonary capillary hemangiomatosis030204 cardiovascular system & hematologypulmonary capillary hemangiomatosisPathology and Forensic Medicine03 medical and health sciencesThree dimensional morphology0302 clinical medicineRight heart failurepulmonary hypertensionmedicinelcsh:PathologyHumansHemangioma CapillaryLungNeovascularization Pathologicbusiness.industryBrief Definitive Reportintussusceptive neoangiogenesismedicine.diseasePulmonary hypertension3. Good healthmedicine.anatomical_structurePulmonary VeinsLung disease030220 oncology & carcinogenesisPulmonary Veno-Occlusive DiseaseImmunohistochemistryPulmonary Veno-Occlusive Diseasebusinesspulmonary vascular remodelinglcsh:RB1-214The Journal of Pathology: Clinical Research
researchProduct

Treatment of heart failure with preserved ejection fraction.

2018

Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to high mortality and the frequent need for hospitalization, with a consequent heavy burden on healthcare resources. For an appropriate treatment of heart failure with preserved ejection fraction (HFpEF), there are no specific drugs effective for this condition. Those indicated in HF with reduced EF (HFrEF) are of more benefit in that form of HF, according to the guidelines of the European Society of Cardiology of 2016: ACE-inhibitors, beta-blockers, anti-aldosterones are all indicated with a class of recommendation/level of evidence IA; therapy with loop diuretics is indicated in the case of clin…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEjection fractionSettore MED/09 - Medicina Internalcsh:Medicineheart failuretherapeutic strategies.Hospitalization rateInternal medicineMedicineAerobic exerciseguidelinesEjection fraction; comorbidity; guidelines; heart failure; therapeutic strategies.Ejection fractionbusiness.industryHigh mortalitylcsh:REvidence-based medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolarecomorbidityHeart failureCardiologyCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessguidelineMonaldi archives for chest disease = Archivio Monaldi per le malattie del torace
researchProduct

S3-Leitlinie „Einsatz der intraaortalen Ballongegenpulsation in der Herzchirurgie“

2015

Although intra-aortic balloon pumping (IABP) is the most frequently used mechanical cardiac assist device in cardiothoracic surgery, there are only guidelines for substantive sections of aortic counterpulsation including prophylactic and postoperative use. In contrast, evidence-based recommendations are still lacking concerning intraoperative use, management, contraindication and other relevant issues. According to international surveys, important aspects of IABP usage show a wide variation in clinical practice. The results of a national questionnaire performed before initiation of this guideline confirmed these findings and demonstrated a clear need for the development of a consensus-based…

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryMEDLINEMedizinEvidence-based medicineGuidelinelanguage.human_languageGermanRight heart failureCardiothoracic surgeryIntensive caremedicinelanguageSurgeryCardiology and Cardiovascular MedicineIntensive care medicinebusinessContraindication
researchProduct

Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. R…

2022

Abstract Background Findings from the T.O.S.CA. Registry recently reported that patients with concomitant chronic heart failure (CHF) and impairment of insulin axis (either insulin resistance—IR or diabetes mellitus—T2D) display increased morbidity and mortality. However, little information is available on the relative impact of IR and T2D on cardiac structure and function, cardiopulmonary performance, and their longitudinal changes in CHF. Methods Patients enrolled in the T.O.S.CA. Registry performed echocardiography and cardiopulmonary exercise test at baseline and at a patient-average follow-up of 36 months. Patients were divided into three groups based on the degree of insulin impairmen…

RegistrieHeart FailureEndocrinology Diabetes and MetabolismVentricular Dysfunction RightDiabetesInsulinsSocio-culturaleStroke VolumeInsulin resistanceDiabeteCardiopulmonary exercise test Chronic heart failure Diabetes Insulin resistance Right ventricle TOSCA Registry..Chronic heart failureDiabetes Mellitus Type 2TOSCA RegistryExercise TestVentricular Function RightHumansInsulinRight ventricleRegistriesCardiology and Cardiovascular MedicineCardiopulmonary exercise testTOSCAHumanLS4_7
researchProduct